Influenza in Birds: all 115 studies

Page 1 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Smart Analysis and Decision-Making for Emerging Infectious DiseasesEnrolling by invitationNCT07678619Not applicable
• Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older AdultsRecruitingNCT06842173Phase 1/2
• A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or UnprimedCompletedNCT05422326Phase 2Results posted
• 2017 A/H7N9 IIV RevaccinationCompletedNCT03738241Phase 2Results posted
• Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedNCT03682120Phase 2Results posted
• 2013/2017 H7N9 Prime-Boost IntervalCompletedNCT03589807Phase 2Results posted
• Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4CompletedNCT03318315Phase 2Results posted
• Sanofi 2017 H7N9 With/Without AS03 in Adults/ElderlyCompletedNCT03312231Phase 2Results posted
• H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology AnalysesCompletedNCT02921997Phase 2Results posted
• A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgeCompletedNCT02839330Phase 3Results posted
• Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 AdjuvantCompletedNCT02680002Phase 2Results posted
• A Safety and Immunogenicity Study of IVACFLU-A/H5N1CompletedNCT02612909Phase 2/3Results posted
• Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1CompletedNCT02171819Phase 1Results posted
• Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 YearsCompletedNCT01928472Phase 1Results posted
• Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)CompletedNCT01910519Phase 2Results posted
• Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) ExposureCompletedNCT01788228Phase 3Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenCompletedNCT01776554Phase 2Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy AdultsCompletedNCT01776541Phase 2Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsCompletedNCT01766921Phase 2Results posted
• Immune Responses to H5N1 Vaccine With and Without AS03 AdjuvantCompletedNCT01578317Phase 1/2Results posted
• Safety Trial of Live Attenuated Influenza (H7N3) VaccineCompletedNCT01511419Phase 1Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in AdultsCompletedNCT01416571Phase 2Results posted
• Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of AgeCompletedNCT01310413Phase 3Results posted
• Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy AdultsCompletedNCT00868218Phase 1Results posted
• H5N1 Priming and Boosting StrategiesCompletedNCT00703053Phase 2Results posted
• A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64CompletedNCT00695669Phase 2Results posted
• Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult SubjectsCompletedNCT00481065Phase 2Results posted
• Development of Immune Globulin Treatment for Avian FluTerminatedNCT00383071Phase 2Results posted
• High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian InfluenzaCompletedNCT00298233Phase 2Results posted
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07496450Phase 3
• Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartActive, not recruitingNCT07275060Phase 4
• Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)Active, not recruitingNCT07240558Phase 3
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsCompletedNCT07019883Phase 1
• A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older AdultsCompletedNCT06382311Phase 1/2
• Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A InfectionNo longer availableNCT03834376
• A Study of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03755427Phase 2
• Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy AdultsCompletedNCT03745274Phase 1
• Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza VaccineStatus unknownNCT03739229Phase 1
• H5N1 With or Without Topical Aldara in Healthy AdultsCompletedNCT03472976Phase 1
• A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03369808Phase 1/2
• Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in BrazilCompletedNCT03330899Phase 1
• Recombinant H7 Hemagglutinin Influenza Vaccine TrialCompletedNCT03038776Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: ImmunologyCompletedNCT03014310Phase 1
• Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 AdjuvantCompletedNCT02957656Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedNCT02624219Phase 1
• H7N9 Boost in Healthy AdultsCompletedNCT02586792Phase 2
• Safety and Pharmacokinetics Study of FBF001CompletedNCT02295813Phase 1
• Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years OldCompletedNCT02274545Phase 1
• A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus VaccineCompletedNCT02251288Phase 1
• Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 VaccineCompletedNCT02229357Phase 2
• H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedNCT02213354Phase 2
• H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...CompletedNCT02206464Phase 1
• Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying IntervalsCompletedNCT02151344Phase 1
• Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza VaccineCompletedNCT02107807Phase 3
• A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ AdjuvantCompletedNCT02078674Phase 1/2
• Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy AdultsCompletedNCT01995695Phase 1
• H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
• H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2
• A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1CompletedNCT01897701Phase 1
• Immunogenicity of ND1.1 by Delivery Directly to the IleumCompletedNCT01698060Phase 1
• A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and AdultsWithdrawnNCT01676675Phase 1
• A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza VaccineCompletedNCT01675284Phase 1
• Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49CompletedNCT01658800Phase 1
• H5-VLP + GLA-AF Vaccine Trial in Healthy Adult VolunteersCompletedNCT01657929Phase 1
• Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai VolunteersCompletedNCT01656356Phase 1
• H5N1 Vaccination With and Without AS03: Systems Biology AnalysisCompletedNCT01573312Phase 1
• Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 YearsCompletedNCT01560793Phase 1
• Experimental AD4-H5-VTN Vaccine in Healthy VolunteersCompletedNCT01443936Phase 1
• Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza VaccineCompletedNCT01443663Phase 1
• H5N1 Vaccine Study in Japanese AdultsCompletedNCT01382329Phase 2/3
• Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 VaccineCompletedNCT01353534Phase 1/2
• Safety Study of an Oral Vaccine to Prevent Avian InfluenzaCompletedNCT01335347Phase 1
• H5N1 Mix and Match With AS03CompletedNCT01317758Phase 1
• H5N1 Mix and Match With MF59CompletedNCT01317745Phase 1
• Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young AdultsCompletedNCT01258062Phase 1
• Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In AdultsCompletedNCT01250795Phase 1
• Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed AdultsCompletedNCT01195038Phase 2
• Studies of Avian Influenza Transmission to Humans in EgyptCompletedNCT01150552
• Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy AdultsCompletedNCT01142362Phase 1
• Avian Influenza Studies In LebanonCompletedNCT01107262
• An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...CompletedNCT01086657Phase 1
• Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 VaccinesCompletedNCT01086566Phase 1
• Host Genetic Susceptibility to Avian Influenza A/H5N1CompletedNCT01074736
• Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and AdolescentsCompletedNCT01052402Phase 1/2
• Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) ExposureWithdrawnNCT01045564Phase 2
• Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza VirusCompletedNCT01044095Not applicable
• Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young AdultsCompletedNCT00980447Phase 2
• Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7CompletedNCT00922259Phase 1
• Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly SubjectsCompletedNCT00914771Phase 2
• Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in AdultsCompletedNCT00895544Phase 1/2
• Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in ChildrenCompletedNCT00884182Phase 2
• Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)CompletedNCT00812019Phase 1
• H5N1 (Clade 2) Vaccination of Adults and ElderlyCompletedNCT00680069Phase 1/2
• Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted VaccineCompletedNCT00664417Phase 1
• Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza VaccineCompletedNCT00561184Phase 2
• Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsCompletedNCT00537524Phase 2
• A/H5N1 Dose Ranging Study With Adjuvant PatchCompletedNCT00532792Phase 1
• Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyCompletedNCT00489931Phase 1
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza VaccinesCompletedNCT00478816Phase 2
• Pharmacologic Study of Oseltamivir in Healthy VolunteersCompletedNCT00439530Phase 1

← Influenza in Birds overview